Investment case
HUTCHMED (China) Limited
HCM · 22 developments mapped · last assessed 2026-09-29
Market Ontology has mapped 22 macro, policy, and market developments to HUTCHMED (China) Limited since 2026-08-28. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.
Valuation
No validated run has been published for HCM yet, so no modelled value is shown. The HCM valuation is in the public catch-up queue.
Subscribers do not wait for the weekly cycle: they run HCM on demand, against live prices and the latest filings, and change any assumption the developments below move.
Filed financials
Current case
- Strongest support
HUTCHMED and AstraZeneca report positive Phase III SANOVO lung cancer trial data
Direct impact from successful clinical trial results for a key pipeline asset, leading to potential regulatory approval and market expansion.
· Moves probability of success for pipeline assets, peak sales estimates for savolitinib, market share in lung cancer treatment
What changed, by assumption
- 2026-08-28China NMPA grants conditional approval for HUTCHMED's ATLED in oncology
- 2026-09-29AstraZeneca Submits US NDA for Savolitinib and Tagrisso in MET-Driven Lung Cancer
- 2026-09-24Hutchmed to Present Phase III Savolitinib NSCLC Trial Results at ESMO 2026 Congress
- 2026-09-24HUTCHMED and AstraZeneca Present Phase III Lung Cancer Data at ESMO
- 2026-09-24HUTCHMED and AstraZeneca to Present Savolitinib Phase III NSCLC Data at ESMO
- 2026-09-24HUTCHMED to Present Phase III Savolitinib Lung Cancer Data at ESMO 2026
- 2026-09-29AstraZeneca files US FDA NDA for savolitinib combo in MET-driven lung cancer
- 2026-09-29AstraZeneca and HUTCHMED Submit US NDA for ORPATHYS Plus TAGRISSO in Lung Cancer
Event impact log
Full ledger →| Date | Mechanism | Direction | Horizon | Impact |
|---|---|---|---|---|
| 2026-09-29 | AstraZeneca files US FDA NDA for savolitinib combo in MET-driven lung cancer | Bullish | 3-12m | 0.70 |
| 2026-09-29 | AstraZeneca and HUTCHMED Submit US NDA for ORPATHYS Plus TAGRISSO in Lung Cancer | Bullish | 3-12m | 0.70 |
| 2026-09-29 | AstraZeneca Submits US NDA for Savolitinib and Tagrisso in MET-Driven Lung Cancer | Bullish | 3-12m | 0.80 |
| 2026-09-28 | HUTCHMED Doses First Patient in Global Phase Ia Trial of HMPL-A830 | Bullish | 1-5y | 0.60 |
| 2026-09-28 | HUTCHMED and GSK Dose First Patient in Phase Ia Trial of KRAS-EGFR Conjugate HMPL-A830 | Bullish | 1-3m | 0.60 |
| 2026-09-28 | HUTCHMED Initiates Global Phase Ia Trial for KRAS-EGFR Conjugate | Bullish | 1-3m | 0.60 |
| 2026-09-28 | HUTCHMED doses first patient in global Phase Ia trial of KRAS-EGFR conjugate | Bullish | 1-3m | 0.60 |
| 2026-09-28 | HUTCHMED doses first patient in Phase Ia trial of KRAS-EGFR conjugate HMPL-A830 | Bullish | 3-12m | 0.60 |
| 2026-09-28 | HUTCHMED and GSK Initiate Global Phase Ia Trial of KRAS-EGFR Conjugate HMPL-A830 | Bullish | 1-3m | 0.60 |
| 2026-09-28 | HUTCHMED and GSK Initiate Phase Ia Trial for KRAS-EGFR Conjugate Therapy | Bullish | 1-5y | 0.60 |
| 2026-09-28 | HUTCHMED Initiates Phase Ia Global Trial of First-in-Class KRAS-EGFR Conjugate | Bullish | 1-3m | 0.70 |
| 2026-09-24 | Hutchmed to Present Phase III Savolitinib NSCLC Trial Results at ESMO 2026 Congress | Bullish | 3-12m | 0.80 |